Otenabant Explained

Otenabant (CP-945,598) is a drug that acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]

See also

Notes and References

  1. Kim MA, Yun H, Kwak H, Kim J, Lee J . Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist . Tetrahedron . 64 . 48 . 10802–10809 . 2008 . 10.1016/j.tet.2008.09.057 .
  2. Woods SC . The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction . Journal of the American Academy of Physician Assistants . Suppl Endocannabinoid . 11. 7–10 . November 2007 . 18047036 . 10.1097/01720610-200711000-00005. 25472128 .
  3. Web site: Pfizer Pharmaceutical News and Media - Pfizer: One of the world's premier biopharmaceutical companies. www.pfizer.com.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Otenabant".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.